Characteristics of patients in CR with and without residual disease at the end of induction 1
| Patient characteristics . | RD (n = 46) . | No RD (n = 142) . | P . |
|---|---|---|---|
| Sex | .734 | ||
| Male, n (%) | 24 (52) | 70 (49) | |
| Female, n (%) | 22 (48) | 72 (51) | |
| Age, y | |||
| Median (range) | 11.7 (0.2-18.3) | 10.4 (0.2-20.8) | .971 |
| 0-2, n (%) | 10 (22) | 37 (26) | .557 |
| 3-10, n (%) | 10 (22) | 40 (28) | .391 |
| 11-21, n (%) | 26 (57) | 65 (46) | .205 |
| Cytogenetic risk groups | |||
| Favorable, n (%) | 6 (15) | 51 (38) | .005 |
| Unfavorable, n (%) | 2 (5) | 2 (2) | .234 |
| Intermediate, n (%) | 33 (80) | 81 (60) | .018 |
| Unknown, n (%) | 5 | 8 | |
| Risk class | |||
| Low risk (Fav. cyto, NPM, CEBPA), n (%) | 10 (24) | 59 (43) | .029 |
| High risk (Unfav. cyto, HR FLT3/ITD), n (%) | 5 (12) | 10 (7) | .343 |
| Standard risk, n (%) | 26 (63) | 67 (49) | .112 |
| Unknown, n (%) | 5 | 6 | |
| Median WBC count, ×103/μL (range) | 21.3 (0.8-250) | 22.5 (0.9-405) | .360 |
| Median BM blasts, % (range) | 70.5 (3-95) | 67 (7.3-100) | .578 |
| Median platelet count, ×103/μL (range) | 53 (7-483) | 37.5 (4-499) | .229 |
| Median hemoglobin level, g/dL (range) | 8.6 (3.6-14) | 8 (3.1-15.2) | .203 |
| CNS disease, n (%) | 1 (2) | 7 (5) | .682 |
| FLT3/ITD+, n (%) | 3 (9) | 9 (7) | .726 |
| WT1 mutation, n (%) | 7 (20) | 9 (7) | .052 |
| NPM1 mutation, n (%) | 0 (0) | 5 (4) | .586 |
| CEBPA mutation, n (%) | 4 (12) | 5 (4) | .099 |
| Treatment outcome, 3-y % ± 2 SE % | |||
| OS from end course 1 | 56 ± 16 | 80 ± 8 | .002 |
| RFS from end course 1 | 30 ± 15 | 65 ± 9 | < .001 |
| RR from end of course 1 | 60 ± 16 | 29 ± 8 | < .001 |
| Patient characteristics . | RD (n = 46) . | No RD (n = 142) . | P . |
|---|---|---|---|
| Sex | .734 | ||
| Male, n (%) | 24 (52) | 70 (49) | |
| Female, n (%) | 22 (48) | 72 (51) | |
| Age, y | |||
| Median (range) | 11.7 (0.2-18.3) | 10.4 (0.2-20.8) | .971 |
| 0-2, n (%) | 10 (22) | 37 (26) | .557 |
| 3-10, n (%) | 10 (22) | 40 (28) | .391 |
| 11-21, n (%) | 26 (57) | 65 (46) | .205 |
| Cytogenetic risk groups | |||
| Favorable, n (%) | 6 (15) | 51 (38) | .005 |
| Unfavorable, n (%) | 2 (5) | 2 (2) | .234 |
| Intermediate, n (%) | 33 (80) | 81 (60) | .018 |
| Unknown, n (%) | 5 | 8 | |
| Risk class | |||
| Low risk (Fav. cyto, NPM, CEBPA), n (%) | 10 (24) | 59 (43) | .029 |
| High risk (Unfav. cyto, HR FLT3/ITD), n (%) | 5 (12) | 10 (7) | .343 |
| Standard risk, n (%) | 26 (63) | 67 (49) | .112 |
| Unknown, n (%) | 5 | 6 | |
| Median WBC count, ×103/μL (range) | 21.3 (0.8-250) | 22.5 (0.9-405) | .360 |
| Median BM blasts, % (range) | 70.5 (3-95) | 67 (7.3-100) | .578 |
| Median platelet count, ×103/μL (range) | 53 (7-483) | 37.5 (4-499) | .229 |
| Median hemoglobin level, g/dL (range) | 8.6 (3.6-14) | 8 (3.1-15.2) | .203 |
| CNS disease, n (%) | 1 (2) | 7 (5) | .682 |
| FLT3/ITD+, n (%) | 3 (9) | 9 (7) | .726 |
| WT1 mutation, n (%) | 7 (20) | 9 (7) | .052 |
| NPM1 mutation, n (%) | 0 (0) | 5 (4) | .586 |
| CEBPA mutation, n (%) | 4 (12) | 5 (4) | .099 |
| Treatment outcome, 3-y % ± 2 SE % | |||
| OS from end course 1 | 56 ± 16 | 80 ± 8 | .002 |
| RFS from end course 1 | 30 ± 15 | 65 ± 9 | < .001 |
| RR from end of course 1 | 60 ± 16 | 29 ± 8 | < .001 |
RD indicates residual disease; Fav, favorable; cyto, cytogenetics; Unfav, unfavorable; HR, hazard ratio; ITD, internal tandem duplication; WBC, white blood cell; OS, overall survival; RFS, relapse-free survival, and RR, relapse risk.